Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way
Sales of key cystic fibrosis drugs will jump in western economies over the next decade, driven by strong uptake of high-cost CFTR modulator therapies and longer use as life expectancies improve, according to a new report by Datamonitor Healthcare.
You may also be interested in...
Phase I and II results for three of Vertex's four next-generation CFTR correctors showed positive effects on pulmonary function when added to two of the company's approved cystic fibrosis therapies. The drugs are moving rapidly forward so that one or two can move into pivotal trials in 2018.
Vertex is spending $160m to acquire Concert's "enhanced" version of its own blockbuster cystic fibrosis treatment Kalydeco, known as CTP-656, in a defensive move that could allow the company to simplify its dosing regimens and differentiate its products against future competition.
With a second Phase III failure in nonsense mutation CF, the New Jersey biotech ends development of ataluren for CF, but continues with the drug in three smaller indications.